Immunotherapy Diagnostics Expertise
Illuminate immunotherapy treatment opportunities with Caris Molecular Intelligence®. We provide oncologists reliable molecular information to inform immunotherapy treatment decisions using validated assays for PD-L1, MSI, TMB and MMR testing in our state-of-the-art laboratory.
- Programmed Death Ligand-1 (PD-L1) is among the most important immune checkpoint proteins that mediate tumor-induced suppression through T-cell downregulation. PD-L1 expression may indicate a more likely response to immunotherapies.
- Microsatellite Instability (MSI) is caused by failure of the DNA mismatch repair (MMR) system. MSI-High correlates to an increase neoantigen burden, which is more likely to respond favorably to immunotherapies.
- Tumor Mutational Burden (TMB) measures the total number of non-synonymous somatic mutations identified per megabase of the genome coding area. Tumors with high TMB likely harbor neoantigens and may respond more favorably to immunotherapies.
- Mismatch Repair (MMR) proteins by IHC: MLH1, MSH2, MSH6, PMS2.
Our Comprehensive Tumor Profiling approach to assess DNA, RNA and Proteins reveals the highest quality molecular blueprint to guide more precise and individualized treatment decisions.